[
  {
    "ts": null,
    "headline": "Tenet Healthcare Jumps 46% YTD & Trades Cheap: Should You Buy Now?",
    "summary": "THC's 46% YTD surge, upgraded outlook, and discounted valuation highlight its strong growth potential.",
    "url": "https://finnhub.io/api/news?id=40db349271aa8cd64935071162d306d50fdd78996fb5eb3165efd321718f3aaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756834380,
      "headline": "Tenet Healthcare Jumps 46% YTD & Trades Cheap: Should You Buy Now?",
      "id": 136613361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HCA",
      "source": "Yahoo",
      "summary": "THC's 46% YTD surge, upgraded outlook, and discounted valuation highlight its strong growth potential.",
      "url": "https://finnhub.io/api/news?id=40db349271aa8cd64935071162d306d50fdd78996fb5eb3165efd321718f3aaa"
    }
  },
  {
    "ts": null,
    "headline": "HCA Healthcare (NYSE:HCA) shareholders have earned a 26% CAGR over the last five years",
    "summary": "The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...",
    "url": "https://finnhub.io/api/news?id=7fd9bd6b655a04d76d5814fbba58e030720af4c1602b53f232590b983813ffb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756814429,
      "headline": "HCA Healthcare (NYSE:HCA) shareholders have earned a 26% CAGR over the last five years",
      "id": 136604404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HCA",
      "source": "Yahoo",
      "summary": "The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...",
      "url": "https://finnhub.io/api/news?id=7fd9bd6b655a04d76d5814fbba58e030720af4c1602b53f232590b983813ffb3"
    }
  },
  {
    "ts": null,
    "headline": "EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to Accelerate US Expansion",
    "summary": "EQT Life Sciences is pleased to announce that the EQT Health Economics strategy has invested in Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company. The USD 44 million Series B financing round was led by EQT Life Sciences and co-led by Advent Life Sciences and British Business Bank (formerly British Patient Capital), with continued support from existing investors Morningside and BGF. The financing includes a non-dilutive contribution from a strategic partnership with HCA",
    "url": "https://finnhub.io/api/news?id=a95575548745cab777f58948f7df36ff6edce111e6b96ffa660184264818b5aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756808820,
      "headline": "EQT Life Sciences Leads USD 44 Million Series B Financing in Cyted Health to Accelerate US Expansion",
      "id": 136604405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HCA",
      "source": "Yahoo",
      "summary": "EQT Life Sciences is pleased to announce that the EQT Health Economics strategy has invested in Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company. The USD 44 million Series B financing round was led by EQT Life Sciences and co-led by Advent Life Sciences and British Business Bank (formerly British Patient Capital), with continued support from existing investors Morningside and BGF. The financing includes a non-dilutive contribution from a strategic partnership with HCA",
      "url": "https://finnhub.io/api/news?id=a95575548745cab777f58948f7df36ff6edce111e6b96ffa660184264818b5aa"
    }
  }
]